肺炎链球菌疫苗市场报告：2030 年趋势、预测与竞争分析

肺炎链球菌疫苗趋势和预测

2030年，全球肺炎链球菌疫苗市场预计将达到112.4亿美元，2024年至2030年的复合年增长率为4.8%。该市场的主要驱动因素是人们对肺炎球菌疫苗接种重要性的认识不断提高、新型和创新性肺炎球菌疫苗的开拓以及政府促进肺炎球菌疫苗接种的配合措施。全球肺炎链球菌疫苗市场的未来性充满希望，肺炎链球菌结合疫苗和肺炎链球菌多醣体疫苗市场充满机会。

肺炎链球菌疫苗市场洞察

Lucintel 预测，prevnar13 预计在预测期内成长最快，因为它可以保护儿童和成人免受 13 种肺炎球菌血清型引起的肺炎球菌疾病。

在这个市场中，肺炎球菌结合疫苗由于能够预防儿童和年轻人的肺炎球菌疾病，预计在预测期内将出现高速成长。

本报告回答了 11 个关键问题：

• Q.1. 细分市场中最有前途和高成长的机会是什么？
• Q.2.哪个细分市场将以更快的速度成长？为什么？
• Q.3.您认为哪些地区未来会出现更快的成长？为什么？
• Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
• Q.5. 这个市场的商业风险和竞争威胁是什么？
• Q.6.这个市场有哪些新趋势？为什么？
• Q.7.市场客户需求有何改变？
• Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
• Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
• Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
• Q.11.过去五年发生了哪些併购事件，对产业产生了哪些影响？

目录

第一章执行摘要

第二章全球肺炎链球菌疫苗市场：市场动态

• 简介、背景、分类
• 供应链
• 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

• 宏观经济趋势（2018-2023）与预测（2024-2030）
• 全球肺炎链球菌疫苗市场趋势（2018-2023）与预测（2024-2030）
• 按产品类型分類的全球肺炎链球菌疫苗市场
  • 普雷夫纳尔 13
  • 新弗洛里克斯
  • 肺炎疫苗23
• 按疫苗类型分類的全球肺炎链球菌疫苗市场
  • 肺炎链球菌结合疫苗
  • 肺炎链球菌多醣体疫苗

第四章 2018-2030年区域市场趋势及预测分析

• 全球肺炎链球菌疫苗市场区域分布
• 北美肺炎链球菌疫苗市场
• 欧洲肺炎链球菌疫苗市场
• 亚太肺炎链球菌疫苗市场
• 其他地区肺炎链球菌疫苗市场

第五章竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 按产品类型分類的全球肺炎链球菌疫苗市场成长机会
  • 按疫苗类型分類的全球肺炎链球菌疫苗市场成长机会
  • 全球肺炎链球菌疫苗市场成长机会（按地区）
• 全球肺炎链球菌疫苗市场的新趋势
• 战略分析
  • 新产品开发
  • 全球肺炎链球菌疫苗市场产能扩张
  • 全球肺炎链球菌疫苗市场的合併、收购与合资企业
  • 认证和许可

第七章主要企业概况

• GlaxoSmithKline
• Pfizer
• Merck
• CSL
• Serum Institute of India

Pneumococcal Vaccine Trends and Forecast

The future of the global pneumococcal vaccine market looks promising with opportunities in the pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine markets. The global pneumococcal vaccine market is expected to reach an estimated $11.24 billion by 2030 with a CAGR of 4.8% from 2024 to 2030. The major drivers for this market are growing awareness of the importance of pneumococcal vaccination, development of new and innovative pneumococcal vaccines, and government initiatives to promote pneumococcal vaccination.

A more than 150-page report is developed to help in your business decisions.

Pneumococcal Vaccine by Segment

The study includes a forecast for the global pneumococcal vaccine by product type, vaccine type, and region.

Pneumococcal Vaccine Market by Product Type [Shipment Analysis by Value from 2018 to 2030]:

• Prevnar 13
• Synflorix
• Pneumovax23

Pneumococcal Vaccine Market by Vaccine Type [Shipment Analysis by Value from 2018 to 2030]:

• Pneumococcal Conjugate Vaccine
• Pneumococcal Polysaccharide Vaccine

Pneumococcal Vaccine Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Pneumococcal Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies pneumococcal vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the pneumococcal vaccine companies profiled in this report include-

• GlaxoSmithKline
• Pfizer
• Merck
• CSL
• Serum Institute of India

Pneumococcal Vaccine Market Insights

Lucintel forecasts that prevnar 13 is expected to witness highest growth over the forecast period due to its ability to protect children and adults from pneumococcal diseases caused by 13 serotypes of streptococcus pneumoniae.

Within this market, pneumococcal conjugate vaccine is expected to witness higher growth over the forecast period due to its capacity to prevent pneumococcal disease in children and young adults.

Features of the Global Pneumococcal Vaccine Market

Market Size Estimates: Pneumococcal vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Pneumococcal vaccine market size by product type, vaccine type, and region in terms of value ($B).

Regional Analysis: Pneumococcal vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, vaccine types, and regions for the pneumococcal vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the pneumococcal vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the pneumococcal vaccine market size?

Answer: The global pneumococcal vaccine market is expected to reach an estimated $11.24 billion by 2030.

Q.2 What is the growth forecast for pneumococcal vaccine market?

Answer: The global pneumococcal vaccine market is expected to grow with a CAGR of 4.8% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the pneumococcal vaccine market?

Answer: The major drivers for this market are growing awareness of the importance of pneumococcal vaccination, development of new and innovative pneumococcal vaccines, and government initiatives to promote pneumococcal vaccination.

Q4. What are the major segments for pneumococcal vaccine market?

Answer: The future of the pneumococcal vaccine market looks promising with opportunities in the pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine markets.

Q5. Who are the key pneumococcal vaccine market companies?

Answer: Some of the key pneumococcal vaccine companies are as follows:

• GlaxoSmithKline
• Pfizer
• Merck
• CSL
• Serum Institute of India

Q6. Which pneumococcal vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that prevnar 13 is expected to witness highest growth over the forecast period due to its ability to protect children and adults from pneumococcal diseases caused by 13 serotypes of streptococcus pneumoniae.

Q7. In pneumococcal vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to high prevalence of pneumococcal disease among population and presence of well-established healthcare system in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the pneumococcal vaccine market by product type (prevnar 13, synflorix, and pneumovax23), vaccine type (pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Pneumococcal Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Pneumococcal Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Pneumococcal Vaccine Market by Product Type
  • 3.3.1: Prevnar 13
  • 3.3.2: Synflorix
  • 3.3.3: Pneumovax23
• 3.4: Global Pneumococcal Vaccine Market by Vaccine Type
  • 3.4.1: Pneumococcal Conjugate Vaccine
  • 3.4.2: Pneumococcal Polysaccharide Vaccine

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Pneumococcal Vaccine Market by Region
• 4.2: North American Pneumococcal Vaccine Market
  • 4.2.2: North American Pneumococcal Vaccine Market by Vaccine Type: Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine
• 4.3: European Pneumococcal Vaccine Market
  • 4.3.1: European Pneumococcal Vaccine Market by Product Type: Prevnar 13, Synflorix, and Pneumovax23
  • 4.3.2: European Pneumococcal Vaccine Market by Vaccine Type: Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine
• 4.4: APAC Pneumococcal Vaccine Market
  • 4.4.1: APAC Pneumococcal Vaccine Market by Product Type: Prevnar 13, Synflorix, and Pneumovax23
  • 4.4.2: APAC Pneumococcal Vaccine Market by Vaccine Type: Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine
• 4.5: ROW Pneumococcal Vaccine Market
  • 4.5.1: ROW Pneumococcal Vaccine Market by Product Type: Prevnar 13, Synflorix, and Pneumovax23
  • 4.5.2: ROW Pneumococcal Vaccine Market by Vaccine Type: Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Pneumococcal Vaccine Market by Product Type
  • 6.1.2: Growth Opportunities for the Global Pneumococcal Vaccine Market by Vaccine Type
  • 6.1.3: Growth Opportunities for the Global Pneumococcal Vaccine Market by Region
• 6.2: Emerging Trends in the Global Pneumococcal Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Pneumococcal Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Pneumococcal Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: GlaxoSmithKline
• 7.2: Pfizer
• 7.3: Merck
• 7.4: CSL
• 7.5: Serum Institute of India